Dexanabinol: Dexanabinone, HU 211, PA 50211, PRS 211007, Sinnabidol

Author：  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.4, Iss.3, 2003-01, pp. : 185-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interaction of Dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system

By Striem S.   Bar-Joseph A.   Berkovitch Y.   Biegon A.  

European Journal of Pharmacology, Vol. 338, Iss. 3, 1997-11 ,pp. : 205-213

Elsevier

Access to resources Recommend Favorite

Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist

By Eshhar N.   Striem S.   Kohen R.   Tirosh O.   Biegon A.  

European Journal of Pharmacology, Vol. 283, Iss. 1, 1995-09 ,pp. : 19-29

Elsevier

Access to resources Recommend Favorite

Dexanabinol promising in severe head injury

By  

Inpharma, Vol. 1, Iss. 1334, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Astatine-211: Production and Availability

By  

Current Radiopharmaceuticals, Vol. 4, Iss. 3, 2011-07 ,pp. : 177-185

Bentham Science Publishers

Access to resources Recommend Favorite

Reteplase (r-PA):

By Bode C.   Kohler B.   Moser M.   Schmittner M.   Smalling R.W.   Strasser R.H.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 8, 1997-08 ,pp. : 1099-1104

Informa Healthcare

Access to resources Recommend Favorite